← back to search

Eva‐Maria Paulus

Novartis (Switzerland) · CH
Area of research
Transplantation · Psychiatry and Mental health
Research interest
Research focused on Everolimus and Calcineurin, with related work in ZEUS (particle detector), Urology, Ranibizumab. Notable publications include 'Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation', 'Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study', and 'Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)'.
h-index
—
citations
280
works
4
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)
Acta Ophthalmologica 2017cited by 66position: middledoi
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial
Nephrology Dialysis Transplantation 2017cited by 35position: middledoi
Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation
American Journal of Transplantation 2014cited by 95position: middledoi
Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study
American Journal of Transplantation 2012cited by 84position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Frank Lehner · Fachhochschule Wiener Neustadt3 papers (2012–2017)Wolfgang Arns · Charité - Universitätsmedizin Berlin2 papers (2012–2017)Klemens Budde · Humboldt-Universität zu Berlin2 papers (2012–2017)Claudia Sommerer · Heidelberg University2 papers (2012–2017)Oliver Witzke · Technische Universität Dresden2 papers (2012–2017)— · 2 papers (2012–2017)M. Mertens · Novartis (Switzerland)1 papers (2014–2014)— · 1 papers (2017–2017)Michael Duerr · Boehringer Ingelheim (Germany)1 papers (2017–2017)M. Loss · University of Regensburg1 papers (2014–2014)Andreas Pascher · University of Münster1 papers (2014–2014)— · 1 papers (2012–2012)Lars‐Olof Hattenbach · Johannes Gutenberg University Mainz1 papers (2017–2017)Ute Eisenberger · KU Leuven1 papers (2012–2012)Nicolas Feltgen · Medizinische Hochschule Hannover1 papers (2017–2017)Peter Schemmer · Medical University of Graz1 papers (2014–2014)Nils Heyne · University of Tübingen1 papers (2014–2014)— · 1 papers (2012–2012)Claudia Weiß · Humboldt-Universität zu Berlin1 papers (2017–2017)Silvio Nadalin · The University of Tokyo1 papers (2014–2014)